Literature DB >> 10996311

Arginine-rich peptides are blockers of VR-1 channels with analgesic activity.

R Planells-Cases1, A Aracil, J M Merino, J Gallar, E Pérez-Payá, C Belmonte, J M González-Ros, A V Ferrer-Montiel.   

Abstract

Vanilloid receptors (VRs) play a fundamental role in the transduction of peripheral tissue injury and/or inflammation responses. Molecules that antagonize VR channel activity may act as selective and potent analgesics. We report that synthetic arginine-rich hexapeptides block heterologously expressed VR-1 channels with submicromolar efficacy in a weak voltage-dependent manner, consistent with a binding site located near/at the entryway of the aqueous pore. Dynorphins, natural arginine-rich peptides, also blocked VR-1 activity with micromolar affinity. Notably, synthetic and natural arginine-rich peptides attenuated the ocular irritation produced by topical capsaicin application onto the eyes of experimental animals. Taken together, our results imply that arginine-rich peptides are VR-1 channel blockers with analgesic activity. These findings may expand the development of novel analgesics by targeting receptor sites distinct from the capsaicin binding site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996311     DOI: 10.1016/s0014-5793(00)01982-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  Poly-arginine and arginine-rich peptides are neuroprotective in stroke models.

Authors:  Bruno P Meloni; Laura M Brookes; Vince W Clark; Jane L Cross; Adam B Edwards; Ryan S Anderton; Richard M Hopkins; Katrin Hoffmann; Neville W Knuckey
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-11       Impact factor: 6.200

2.  Analgesic effect of a polypeptide inhibitor of the TRPV1 receptor in noxious heat pain models.

Authors:  Y A Andreev; S A Kozlov; E P Kozlovskaya; E V Grishin
Journal:  Dokl Biochem Biophys       Date:  2009 Jan-Feb       Impact factor: 0.788

3.  Physiology and pharmacology of the vanilloid receptor.

Authors:  Angel Messeguer; Rosa Planells-Cases; Antonio Ferrer-Montiel
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

4.  Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1).

Authors:  Yaroslav A Andreev; Sergey A Kozlov; Sergey G Koshelev; Ekaterina A Ivanova; Margarita M Monastyrnaya; Emma P Kozlovskaya; Eugene V Grishin
Journal:  J Biol Chem       Date:  2008-06-25       Impact factor: 5.157

5.  Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model.

Authors:  Adam B Edwards; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Mol Cell Biochem       Date:  2016-11-14       Impact factor: 3.396

6.  The Neuroprotective Peptide Poly-Arginine-12 (R12) Reduces Cell Surface Levels of NMDA NR2B Receptor Subunit in Cortical Neurons; Investigation into the Involvement of Endocytic Mechanisms.

Authors:  Gabriella MacDougall; Ryan S Anderton; Adam B Edwards; Neville W Knuckey; Bruno P Meloni
Journal:  J Mol Neurosci       Date:  2016-11-20       Impact factor: 3.444

7.  Attenuation of thermal nociception and hyperalgesia by VR1 blockers.

Authors:  Carolina García-Martinez; Marc Humet; Rosa Planells-Cases; Ana Gomis; Marco Caprini; Felix Viana; Elvira De La Pena; Francisco Sanchez-Baeza; Teresa Carbonell; Carmen De Felipe; Enrique Pérez-Paya; Carlos Belmonte; Angel Messeguer; Antonio Ferrer-Montiel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

8.  Pharmacological modulation of monovalent cation currents through the epithelial Ca2+ channel ECaC1.

Authors:  B Nilius; J Prenen; R Vennekens; J G Hoenderop; R J Bindels; G Droogmans
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide.

Authors:  Weina Ju; Qi Li; Yohance M Allette; Matthew S Ripsch; Fletcher A White; Rajesh Khanna
Journal:  J Neurochem       Date:  2013-01-20       Impact factor: 5.372

10.  Poly-Arginine Peptide-18 (R18) Reduces Brain Injury and Improves Functional Outcomes in a Nonhuman Primate Stroke Model.

Authors:  Bruno P Meloni; Yining Chen; Kathleen A Harrison; Joseph Y Nashed; David J Blacker; Samantha M South; Ryan S Anderton; Frank L Mastaglia; Andrew Winterborn; Neville W Knuckey; Douglas J Cook
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.